Literature DB >> 15851228

Novel pore mutation in SCN5A manifests as a spectrum of phenotypes ranging from atrial flutter, conduction disease, and Brugada syndrome to sudden cardiac death.

Tom Rossenbacker1, Sheila J Carroll, Huajun Liu, Cuno Kuipéri, Thomy J L de Ravel, Koen Devriendt, Peter Carmeliet, Robert S Kass, Hein Heidbüchel.   

Abstract

OBJECTIVES: The purpose of this study was to determine the clinical and biophysical characteristics of a novel SCN5A mutation.
BACKGROUND: Brugada syndrome and isolated cardiac conduction defect have been linked to SCN5A mutations.
METHODS: Eleven members of a western European family underwent electrophysiologic investigations and mutation analysis of the SCN5A gene. Wild-type and mutant SCN5A channels were expressed in HEK293 cells, and whole cell currents were studied using patch clamp procedures.
RESULTS: A novel mutation, R376H, in the first pore segment of SCN5A variably causes Brugada syndrome and/or conduction disease in a single family. Biophysical analysis demonstrated a significant current reduction for the mutant, a pathophysiologic profile consistent with Brugada syndrome and isolated cardiac conduction defect. Among 11 family members, 9 were carriers of the mutation. The proband's initial presentation was a saddleback Brugada ECG, atrial flutter, and diffuse conduction disturbances. He had no inducible ventricular arrhythmias but experienced sudden cardiac death. His brother was affected by atrial flutter and had a clear conduction disorder, but he did not display baseline or evocable ECG signs of Brugada syndrome. He received an implantable cardioverter-defibrillator that delivered one appropriate shock after 1 year of follow-up. The phenotype in the family members was highly variable and ranged from noninducible and inducible asymptomatic carriers of the mutations to isolated conduction disease and to symptomatic Brugada syndrome.
CONCLUSIONS: We describe the functional characterization of a novel SCN5A pore mutation, R376H, with variable clinical expression in the same family. Differentiating between electrophysiologic entities (Brugada syndrome-isolated cardiac conduction defect) is more challenging. Recognition of factors modifying the clinical presentation may be important for clinical decision making.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15851228     DOI: 10.1016/j.hrthm.2004.07.001

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  20 in total

1.  A sodium channel pore mutation causing Brugada syndrome.

Authors:  Arnold E Pfahnl; Prakash C Viswanathan; Raul Weiss; Lijuan L Shang; Shamarendra Sanyal; Vladimir Shusterman; Cari Kornblit; Barry London; Samuel C Dudley
Journal:  Heart Rhythm       Date:  2006-09-28       Impact factor: 6.343

2.  Diversity in cardiac sodium channel disease phenotype in transgenic mice carrying a single SCN5A mutation.

Authors:  C A Remme; A O Verkerk; A A M Wilde; M W Veldkamp; J M T de Bakker; C R Bezzina
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

3.  Genotype-phenotype relationship and risk stratification in loss-of-function SCN5A mutation carriers.

Authors:  Tomas Robyns; Dieter Nuyens; Bert Vandenberk; Cuno Kuiperi; Anniek Corveleyn; Jeroen Breckpot; Christophe Garweg; Joris Ector; Rik Willems
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-04-30       Impact factor: 1.468

4.  Novel SCN5A mutations in two families with "Brugada-like" ST elevation in the inferior leads and conduction disturbances.

Authors:  Philippe Maury; Adrien Moreau; Francoise Hidden-Lucet; Antoine Leenhardt; Veronique Fressart; Myriam Berthet; Isabelle Denjoy; Nawal Bennamar; Anne Rollin; Christelle Cardin; Pascale Guicheney; Mohamed Chahine
Journal:  J Interv Card Electrophysiol       Date:  2013-04-24       Impact factor: 1.900

Review 5.  The outer vestibule of the Na+ channel-toxin receptor and modulator of permeation as well as gating.

Authors:  René Cervenka; Touran Zarrabi; Peter Lukacs; Hannes Todt
Journal:  Mar Drugs       Date:  2010-04-21       Impact factor: 5.118

Review 6.  The cardiac sodium channel gene SCN5A and its gene product NaV1.5: Role in physiology and pathophysiology.

Authors:  Christiaan C Veerman; Arthur A M Wilde; Elisabeth M Lodder
Journal:  Gene       Date:  2015-09-08       Impact factor: 3.688

Review 7.  Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects.

Authors:  Carol Ann Remme
Journal:  J Physiol       Date:  2013-07-01       Impact factor: 5.182

8.  Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation.

Authors:  Dawood Darbar; Prince J Kannankeril; Brian S Donahue; Gayle Kucera; Tanya Stubblefield; Jonathan L Haines; Alfred L George; Dan M Roden
Journal:  Circulation       Date:  2008-03-31       Impact factor: 29.690

9.  Heterozygous nonsense SCN5A mutation W822X explains a simultaneous sudden infant death syndrome.

Authors:  Emanuela Turillazzi; Giampiero La Rocca; Rita Anzalone; Simona Corrao; Margherita Neri; Cristoforo Pomara; Irene Riezzo; Steven B Karch; Vittorio Fineschi
Journal:  Virchows Arch       Date:  2008-06-13       Impact factor: 4.064

10.  Brugada syndrome risk loci seem protective against atrial fibrillation.

Authors:  Laura Andreasen; Jonas B Nielsen; Stine Darkner; Ingrid E Christophersen; Javad Jabbari; Lena Refsgaard; Jens J Thiis; Ahmad Sajadieh; Arnljot Tveit; Stig Haunsø; Jesper H Svendsen; Nicole Schmitt; Morten S Olesen
Journal:  Eur J Hum Genet       Date:  2014-03-26       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.